25 XP   0   0   10

Hubei Biocause Pharmaceutical
Buy, Hold or Sell?

Let's analyse Biocause together

PenkeI guess you are interested in Hubei Biocause Pharmaceutical. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Hubei Biocause Pharmaceutical. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Hubei Biocause Pharmaceutical

I send you an email if I find something interesting about Hubei Biocause Pharmaceutical.

Quick analysis of Biocause (30 sec.)










What can you expect buying and holding a share of Biocause? (30 sec.)

How much money do you get?

How much money do you get?
¥0.08
When do you have the money?
1 year
How often do you get paid?
90.0%

What is your share worth?

Current worth
¥7.00
Expected worth in 1 year
¥4.68
How sure are you?
70.0%

+ What do you gain per year?

Total Gains per Share
¥-1.76
Return On Investment
-75.5%

For what price can you sell your share?

Current Price per Share
¥2.33
Expected price per share
¥2.11 - ¥2.59
How sure are you?
50%

1. Valuation of Biocause (5 min.)




Live pricePrice per Share (EOD)

¥2.33

Intrinsic Value Per Share

¥-39.77 - ¥39.93

Total Value Per Share

¥-32.76 - ¥46.94

2. Growth of Biocause (5 min.)




Is Biocause growing?

Current yearPrevious yearGrowGrow %
How rich?$4.7b$5.1b-$396.8m-8.3%

How much money is Biocause making?

Current yearPrevious yearGrowGrow %
Making money$37.8m$65m-$27.1m-71.8%
Net Profit Margin0.6%3.9%--

How much money comes from the company's main activities?

3. Financial Health of Biocause (5 min.)




What can you expect buying and holding a share of Biocause? (5 min.)

Welcome investor! Biocause's management wants to use your money to grow the business. In return you get a share of Biocause.

What can you expect buying and holding a share of Biocause?

First you should know what it really means to hold a share of Biocause. And how you can make/lose money.

Speculation

The Price per Share of Biocause is ¥2.33. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Biocause.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Biocause, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is ¥7.00. Based on the TTM, the Book Value Change Per Share is ¥-0.58 per quarter. Based on the YOY, the Book Value Change Per Share is ¥0.58 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is ¥0.14 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Biocause.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 ¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share¥% of Price per Share
Usd Eps0.010.3%0.010.3%0.010.6%0.021.1%0.020.9%
Usd Book Value Change Per Share-0.08-3.4%-0.08-3.4%0.083.5%0.041.9%0.094.0%
Usd Dividend Per Share0.020.8%0.020.8%0.010.5%0.010.5%0.010.3%
Usd Total Gains Per Share-0.06-2.6%-0.06-2.6%0.093.9%0.062.4%0.104.3%
Usd Price Per Share0.44-0.44-0.46-0.66-0.79-
Price to Earnings Ratio56.97-56.97-34.74-34.73-68.14-
Price-to-Total Gains Ratio-7.19--7.19-5.00--8.72-28.93-
Price to Book Ratio0.45-0.45-0.44-0.73-5.94-
Price-to-Total Gains Ratio-7.19--7.19-5.00--8.72-28.93-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.322006
Number of shares3105
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.020.01
Usd Book Value Change Per Share-0.080.04
Usd Total Gains Per Share-0.060.06
Gains per Quarter (3105 shares)-188.68176.60
Gains per Year (3105 shares)-754.71706.40
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
1243-998-765158549696
2486-1995-152031510981402
3729-2993-227547316462108
4972-3991-303063021952814
51215-4988-378578827443520
61458-5986-454094632934226
71701-6984-5295110338414932
81944-7982-6050126143905638
92187-8979-6805141949396344
102430-9977-7560157654887050

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%9.00.01.090.0%20.00.03.087.0%
Book Value Change Per Share0.01.00.00.0%2.01.00.066.7%3.02.00.060.0%7.03.00.070.0%17.06.00.073.9%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%5.00.00.0100.0%9.00.01.090.0%22.00.01.095.7%
Total Gains per Share0.01.00.00.0%2.01.00.066.7%3.02.00.060.0%7.03.00.070.0%18.05.00.078.3%

Fundamentals of Biocause

About Hubei Biocause Pharmaceutical

Hubei Biocause Pharmaceutical Co., Ltd. primarily provides life and motor insurance products in China. It also engages in the pharmaceutical, chemical, and new energy fuel businesses. In addition, the company is involved in the contract research and production of APIs, intermediates, and formulations, including tablets, granules, capsules, etc.; and provision of chemicals comprising dimethyl ether gas and a-chloropropionyl chloride. It exports its products to approximately 85 countries, including the United States, the European Union, and internationally. The company is based in Jingmen, China.

Fundamental data was last updated by Penke on 2024-04-13 17:27:04.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is not making a profit/loss.
Using its assets, the company is inefficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating inefficient.
The company is very efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is able to pay all its short-term debts.
The company is just not able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is just able to pay all its debts by selling its assets.
The company is unable to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is cheap.

1.1. Profitability of Hubei Biocause Pharmaceutical.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Biocause earns for each ¥1 of revenue.

  • Above 10% is considered healthy but always compare Biocause to the Insurance - Life industry mean.
  • A Net Profit Margin of 0.6% means that ¥0.01 for each ¥1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Hubei Biocause Pharmaceutical:

  • The MRQ is 0.6%. The company is not making a profit/loss.
  • The TTM is 0.6%. The company is not making a profit/loss.
Trends
Current periodCompared to+/- 
MRQ0.6%TTM0.6%0.0%
TTM0.6%YOY3.9%-3.3%
TTM0.6%5Y7.0%-6.5%
5Y7.0%10Y10.2%-3.2%
1.1.2. Return on Assets

Shows how efficient Biocause is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Biocause to the Insurance - Life industry mean.
  • 0.1% Return on Assets means that Biocause generated ¥0.00 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Hubei Biocause Pharmaceutical:

  • The MRQ is 0.1%. Using its assets, the company is inefficient in making profit. -1
  • The TTM is 0.1%. Using its assets, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ0.1%TTM0.1%0.0%
TTM0.1%YOY0.2%-0.1%
TTM0.1%5Y0.4%-0.3%
5Y0.4%10Y1.9%-1.5%
1.1.3. Return on Equity

Shows how efficient Biocause is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Biocause to the Insurance - Life industry mean.
  • 1.3% Return on Equity means Biocause generated ¥0.01 for each ¥1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Hubei Biocause Pharmaceutical:

  • The MRQ is 1.3%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 1.3%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ1.3%TTM1.3%0.0%
TTM1.3%YOY2.1%-0.8%
TTM1.3%5Y4.3%-3.0%
5Y4.3%10Y6.1%-1.8%

1.2. Operating Efficiency of Hubei Biocause Pharmaceutical.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Biocause is operating .

  • Measures how much profit Biocause makes for each ¥1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Biocause to the Insurance - Life industry mean.
  • An Operating Margin of 0.5% means the company generated ¥0.00  for each ¥1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Hubei Biocause Pharmaceutical:

  • The MRQ is 0.5%. The company is operating inefficient. -1
  • The TTM is 0.5%. The company is operating inefficient. -1
Trends
Current periodCompared to+/- 
MRQ0.5%TTM0.5%0.0%
TTM0.5%YOY2.5%-2.0%
TTM0.5%5Y12.6%-12.1%
5Y12.6%10Y19.8%-7.2%
1.2.2. Operating Ratio

Measures how efficient Biocause is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Insurance - Life industry mean).
  • An Operation Ratio of 0.55 means that the operating costs are ¥0.55 for each ¥1 in net sales.

Let's take a look of the Operating Ratio trends of Hubei Biocause Pharmaceutical:

  • The MRQ is 0.546. The company is very efficient in keeping operating costs low. +2
  • The TTM is 0.546. The company is very efficient in keeping operating costs low. +2
Trends
Current periodCompared to+/- 
MRQ0.546TTM0.5460.000
TTM0.546YOY1.197-0.651
TTM0.5465Y0.721-0.175
5Y0.72110Y0.702+0.019

1.3. Liquidity of Hubei Biocause Pharmaceutical.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Biocause is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Insurance - Life industry mean).
  • A Current Ratio of 2.24 means the company has ¥2.24 in assets for each ¥1 in short-term debts.

Let's take a look of the Current Ratio trends of Hubei Biocause Pharmaceutical:

  • The MRQ is 2.240. The company is able to pay all its short-term debts. +1
  • The TTM is 2.240. The company is able to pay all its short-term debts. +1
Trends
Current periodCompared to+/- 
MRQ2.240TTM2.2400.000
TTM2.240YOY3.787-1.547
TTM2.2405Y3.444-1.204
5Y3.44410Y2.561+0.883
1.3.2. Quick Ratio

Measures if Biocause is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Biocause to the Insurance - Life industry mean.
  • A Quick Ratio of 0.09 means the company can pay off ¥0.09 for each ¥1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Hubei Biocause Pharmaceutical:

  • The MRQ is 0.087. The company is just not able to pay all its short-term debts with the most liquid assets. -1
  • The TTM is 0.087. The company is just not able to pay all its short-term debts with the most liquid assets. -1
Trends
Current periodCompared to+/- 
MRQ0.087TTM0.0870.000
TTM0.087YOY0.497-0.410
TTM0.0875Y0.354-0.268
5Y0.35410Y0.517-0.163

1.4. Solvency of Hubei Biocause Pharmaceutical.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Biocause assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Biocause to Insurance - Life industry mean.
  • A Debt to Asset Ratio of 0.88 means that Biocause assets are financed with 88.0% credit (debt) and the remaining percentage (100% - 88.0%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Hubei Biocause Pharmaceutical:

  • The MRQ is 0.880. The company is just able to pay all its debts by selling its assets.
  • The TTM is 0.880. The company is just able to pay all its debts by selling its assets.
Trends
Current periodCompared to+/- 
MRQ0.880TTM0.8800.000
TTM0.880YOY0.858+0.022
TTM0.8805Y0.856+0.024
5Y0.85610Y0.680+0.176
1.4.2. Debt to Equity Ratio

Measures if Biocause is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Biocause to the Insurance - Life industry mean.
  • A Debt to Equity ratio of 1,186.2% means that company has ¥11.86 debt for each ¥1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Hubei Biocause Pharmaceutical:

  • The MRQ is 11.862. The company is unable to pay all its debts with equity. -1
  • The TTM is 11.862. The company is unable to pay all its debts with equity. -1
Trends
Current periodCompared to+/- 
MRQ11.862TTM11.8620.000
TTM11.862YOY10.040+1.823
TTM11.8625Y9.532+2.330
5Y9.53210Y6.191+3.342

2. Market Valuation of Hubei Biocause Pharmaceutical

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ¥1 in earnings Biocause generates.

  • Above 15 is considered overpriced but always compare Biocause to the Insurance - Life industry mean.
  • A PE ratio of 56.97 means the investor is paying ¥56.97 for every ¥1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Hubei Biocause Pharmaceutical:

  • The EOD is 42.006. Based on the earnings, the company is overpriced. -1
  • The MRQ is 56.969. Based on the earnings, the company is expensive. -2
  • The TTM is 56.969. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD42.006MRQ56.969-14.963
MRQ56.969TTM56.9690.000
TTM56.969YOY34.742+22.227
TTM56.9695Y34.731+22.238
5Y34.73110Y68.136-33.405
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Hubei Biocause Pharmaceutical:

  • The EOD is 1.558. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The MRQ is 2.113. Based on how much money comes from the company's main activities, the company is cheap. +2
  • The TTM is 2.113. Based on how much money comes from the company's main activities, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD1.558MRQ2.113-0.555
MRQ2.113TTM2.1130.000
TTM2.113YOY4.209-2.096
TTM2.1135Y2.119-0.006
5Y2.11910Y-169.300+171.419
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Biocause is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Insurance - Life industry mean).
  • A PB ratio of 0.45 means the investor is paying ¥0.45 for each ¥1 in book value.

Let's take a look of the Price to Book Ratio trends of Hubei Biocause Pharmaceutical:

  • The EOD is 0.333. Based on the equity, the company is cheap. +2
  • The MRQ is 0.451. Based on the equity, the company is cheap. +2
  • The TTM is 0.451. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD0.333MRQ0.451-0.119
MRQ0.451TTM0.4510.000
TTM0.451YOY0.436+0.015
TTM0.4515Y0.732-0.281
5Y0.73210Y5.941-5.209
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Hubei Biocause Pharmaceutical compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.581-0.5810%0.584-199%0.320-282%0.669-187%
Book Value Per Share--7.0047.0040%7.585-8%6.762+4%4.430+58%
Current Ratio--2.2402.2400%3.787-41%3.444-35%2.561-13%
Debt To Asset Ratio--0.8800.8800%0.858+3%0.856+3%0.680+29%
Debt To Equity Ratio--11.86211.8620%10.040+18%9.532+24%6.191+92%
Dividend Per Share--0.1420.1420%0.077+83%0.092+54%0.054+161%
Eps--0.0550.0550%0.095-42%0.179-69%0.159-65%
Free Cash Flow Per Share--1.4961.4960%0.786+90%3.035-51%1.541-3%
Free Cash Flow To Equity Per Share--1.4961.4960%2.329-36%3.450-57%2.248-33%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%0.900+11%
Intrinsic Value_10Y_max--39.933--------
Intrinsic Value_10Y_min---39.766--------
Intrinsic Value_1Y_max--3.251--------
Intrinsic Value_1Y_min--0.149--------
Intrinsic Value_3Y_max--10.339--------
Intrinsic Value_3Y_min---3.130--------
Intrinsic Value_5Y_max--18.118--------
Intrinsic Value_5Y_min---10.305--------
Market Cap11511667937.280-36%15612390850.56015612390850.5600%16353485352.960-5%23705142816.768-34%28220878651.392-45%
Net Profit Margin--0.0060.0060%0.039-86%0.070-92%0.102-95%
Operating Margin--0.0050.0050%0.025-80%0.126-96%0.198-98%
Operating Ratio--0.5460.5460%1.197-54%0.721-24%0.702-22%
Pb Ratio0.333-36%0.4510.4510%0.436+3%0.732-38%5.941-92%
Pe Ratio42.006-36%56.96956.9690%34.742+64%34.731+64%68.136-16%
Price Per Share2.330-36%3.1603.1600%3.310-5%4.798-34%5.712-45%
Price To Free Cash Flow Ratio1.558-36%2.1132.1130%4.209-50%2.1190%-169.300+8113%
Price To Total Gains Ratio-5.299+26%-7.187-7.1870%5.004-244%-8.724+21%28.930-125%
Quick Ratio--0.0870.0870%0.497-83%0.354-76%0.517-83%
Return On Assets--0.0010.0010%0.002-47%0.004-78%0.019-95%
Return On Equity--0.0130.0130%0.021-39%0.043-70%0.061-79%
Total Gains Per Share---0.440-0.4400%0.661-166%0.412-207%0.724-161%
Usd Book Value--4782122267.4584782122267.4580%5179000594.174-8%4616806662.652+4%3024446138.154+58%
Usd Book Value Change Per Share---0.080-0.0800%0.081-199%0.044-282%0.092-187%
Usd Book Value Per Share--0.9680.9680%1.048-8%0.934+4%0.612+58%
Usd Dividend Per Share--0.0200.0200%0.011+83%0.013+54%0.007+161%
Usd Eps--0.0080.0080%0.013-42%0.025-69%0.022-65%
Usd Free Cash Flow--1021178699.2631021178699.2630%536972700.057+90%2072348133.327-51%946775611.257+8%
Usd Free Cash Flow Per Share--0.2070.2070%0.109+90%0.419-51%0.213-3%
Usd Free Cash Flow To Equity Per Share--0.2070.2070%0.322-36%0.477-57%0.311-33%
Usd Market Cap1590912508.932-36%2157632415.5472157632415.5470%2260051675.779-5%3276050737.277-34%3900125429.622-45%
Usd Price Per Share0.322-36%0.4370.4370%0.457-5%0.663-34%0.789-45%
Usd Profit--37873864.37537873864.3750%65052627.860-42%122376442.017-69%108673364.810-65%
Usd Revenue--6856889060.0736856889060.0730%1685948415.606+307%2702720922.916+154%1632555101.496+320%
Usd Total Gains Per Share---0.061-0.0610%0.091-166%0.057-207%0.100-161%
 EOD+5 -3MRQTTM+0 -0YOY+9 -265Y+11 -2410Y+12 -24

3.2. Fundamental Score

Let's check the fundamental score of Hubei Biocause Pharmaceutical based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1542.006
Price to Book Ratio (EOD)Between0-10.333
Net Profit Margin (MRQ)Greater than00.006
Operating Margin (MRQ)Greater than00.005
Quick Ratio (MRQ)Greater than10.087
Current Ratio (MRQ)Greater than12.240
Debt to Asset Ratio (MRQ)Less than10.880
Debt to Equity Ratio (MRQ)Less than111.862
Return on Equity (MRQ)Greater than0.150.013
Return on Assets (MRQ)Greater than0.050.001
Total5/10 (50.0%)

3.3. Technical Score

Let's check the technical score of Hubei Biocause Pharmaceutical based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.582
Ma 20Greater thanMa 502.450
Ma 50Greater thanMa 1002.546
Ma 100Greater thanMa 2002.704
OpenGreater thanClose2.270
Total0/5 (0.0%)



Latest Balance Sheet

Balance Sheet of 2022-12-31. Currency in CNY. All numbers in thousands.

Summary
Total Assets288,598,690
Total Liabilities253,995,779
Total Stockholder Equity21,411,956
 As reported
Total Liabilities 253,995,779
Total Stockholder Equity+ 21,411,956
Total Assets = 288,598,690

Assets

Total Assets288,598,690
Total Current Assets55,977,586
Long-term Assets232,621,104
Total Current Assets
Cash And Cash Equivalents 26,309,323
Short-term Investments 2,082,502
Net Receivables 82,684
Inventory 10,504,019
Total Current Assets  (as reported)55,977,586
Total Current Assets  (calculated)38,978,528
+/- 16,999,057
Long-term Assets
Property Plant Equipment 844,066
Goodwill 6,192,211
Intangible Assets 299,340
Long-term Assets Other 6,046,732
Long-term Assets  (as reported)232,621,104
Long-term Assets  (calculated)13,382,348
+/- 219,238,756

Liabilities & Shareholders' Equity

Total Current Liabilities24,985,753
Long-term Liabilities229,010,026
Total Stockholder Equity21,411,956
Total Current Liabilities
Short Long Term Debt 21,189,583
Accounts payable 206,898
Other Current Liabilities 231,461
Total Current Liabilities  (as reported)24,985,753
Total Current Liabilities  (calculated)21,627,943
+/- 3,357,810
Long-term Liabilities
Long term Debt 6,788,309
Capital Lease Obligations Min Short Term Debt89,581
Long-term Liabilities Other 57,516,444
Long-term Liabilities  (as reported)229,010,026
Long-term Liabilities  (calculated)64,394,335
+/- 164,615,692
Total Stockholder Equity
Retained Earnings 6,508,547
Total Stockholder Equity (as reported)21,411,956
Total Stockholder Equity (calculated)6,508,547
+/- 14,903,409
Other
Capital Stock4,940,629
Common Stock Shares Outstanding 4,940,629
Net Debt 1,668,569
Net Invested Capital 49,389,848
Net Tangible Assets 14,767,375
Net Working Capital 30,991,833
Property Plant and Equipment Gross 844,066



Balance Sheet

Currency in CNY. All numbers in thousands.

 Trend2022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-312015-12-312014-12-312013-12-312012-12-312011-12-312010-12-312009-12-312008-12-312007-12-312006-12-312005-12-312004-12-312003-12-312002-12-312001-12-312000-12-31
> Total Assets 
886,331
989,088
1,090,404
1,090,972
1,081,322
1,087,924
1,167,374
1,324,548
1,979,521
2,155,730
1,976,311
1,883,615
2,064,728
2,156,952
2,108,498
2,409,213
117,876,722
140,416,708
178,254,021
205,273,946
239,402,637
263,903,966
288,598,690
288,598,690263,903,966239,402,637205,273,946178,254,021140,416,708117,876,7222,409,2132,108,4982,156,9522,064,7281,883,6151,976,3112,155,7301,979,5211,324,5481,167,3741,087,9241,081,3221,090,9721,090,404989,088886,331
   > Total Current Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
281,474
19,382,238
26,992,585
49,315,681
25,157,491
50,904,240
49,458,013
55,977,586
55,977,58649,458,01350,904,24025,157,49149,315,68126,992,58519,382,238281,474000000000000000
       Cash And Cash Equivalents 
104,854
247,037
72,316
55,491
16,833
26,871
72,210
108,046
290,634
95,114
72,870
74,128
152,836
124,281
58,937
61,635
10,953,168
11,172,135
18,317,496
12,991,688
26,857,149
23,250,296
26,309,323
26,309,32323,250,29626,857,14912,991,68818,317,49611,172,13510,953,16861,63558,937124,281152,83674,12872,87095,114290,634108,04672,21026,87116,83355,49172,316247,037104,854
       Short-term Investments 
0
0
1,362
0
0
0
1,340
3,218
16,082
0
0
0
0
0
0
0
0
4,164,780
0
2,211,804
3,563,328
2,907,532
2,082,502
2,082,5022,907,5323,563,3282,211,80404,164,7800000000016,0823,2181,3400001,36200
       Net Receivables 
172,702
156,558
235,750
256,931
182,671
208,329
171,358
142,299
82,297
98,298
102,462
130,751
168,986
85,377
94,653
69,615
6,893,295
7,545,766
7,954,119
1,508,530
15,932
3,576,792
82,684
82,6843,576,79215,9321,508,5307,954,1197,545,7666,893,29569,61594,65385,377168,986130,751102,46298,29882,297142,299171,358208,329182,671256,931235,750156,558172,702
       Other Current Assets 
27,736
33,799
44,941
29,715
93,609
73,094
53,507
55,969
121,755
168,140
140,967
214,803
71,412
95,156
99,994
14,102
1,121,583
3,562,125
19,223,574
4,073,828
7,378,889
7,099,644
0
07,099,6447,378,8894,073,82819,223,5743,562,1251,121,58314,10299,99495,15671,412214,803140,967168,140121,75555,96953,50773,09493,60929,71544,94133,79927,736
   > Long-term Assets 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
98,141,847
113,022,209
128,435,433
179,488,944
187,659,586
213,545,540
232,621,104
232,621,104213,545,540187,659,586179,488,944128,435,433113,022,20998,141,8470000000000000000
       Property Plant Equipment 
355,083
262,877
322,206
338,442
343,268
484,556
557,143
634,627
895,438
1,130,007
909,503
811,970
956,701
967,206
454,177
334,688
587,407
700,396
770,872
567,167
580,443
830,328
844,066
844,066830,328580,443567,167770,872700,396587,407334,688454,177967,206956,701811,970909,5031,130,007895,438634,627557,143484,556343,268338,442322,206262,877355,083
       Goodwill 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
6,186,323
6,186,323
6,186,323
6,186,323
6,192,211
6,192,211
6,192,211
6,192,2116,192,2116,192,2116,186,3236,186,3236,186,3236,186,3230000000000000000
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,160,618
64,049,830
62,116,817
76,955,896
13,096,141
12,389,541
119,169,195
0
0119,169,19512,389,54113,096,14176,955,89662,116,81764,049,8301,160,618000000000000000
       Intangible Assets 
105,046
123,538
184,430
189,075
186,789
31,634
28,189
35,344
33,402
32,066
28,023
19,706
19,729
15,541
503,876
490,450
549,064
519,902
213,353
109,418
189,999
269,706
299,340
299,340269,706189,999109,418213,353519,902549,064490,450503,87615,54119,72919,70628,02332,06633,40235,34428,18931,634186,789189,075184,430123,538105,046
       Long-term Assets Other 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
23,734,232
35,905,395
5,100,067
4,914,041
5,671,584
8,406,697
6,046,732
6,046,7328,406,6975,671,5844,914,0415,100,06735,905,39523,734,2320000000000000000
> Total Liabilities 
291,809
226,094
322,388
372,217
357,407
356,697
443,661
458,516
466,749
581,286
374,250
469,470
527,369
720,709
618,756
625,498
97,479,212
113,711,848
152,239,478
170,920,472
204,814,717
226,429,287
253,995,779
253,995,779226,429,287204,814,717170,920,472152,239,478113,711,84897,479,212625,498618,756720,709527,369469,470374,250581,286466,749458,516443,661356,697357,407372,217322,388226,094291,809
   > Total Current Liabilities 
282,809
226,094
322,388
372,217
357,407
356,697
413,661
428,485
306,563
356,286
239,750
334,970
492,569
704,897
577,496
415,037
3,809,823
10,286,372
26,486,417
8,433,861
8,016,359
13,059,854
24,985,753
24,985,75313,059,8548,016,3598,433,86126,486,41710,286,3723,809,823415,037577,496704,897492,569334,970239,750356,286306,563428,485413,661356,697357,407372,217322,388226,094282,809
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
414,000
275,000
29,000
0
0
0
0
000029,000275,000414,0000000000000000000
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
414,000
275,000
29,000
6,179,753
4,583,818
9,425,768
21,189,583
21,189,5839,425,7684,583,8186,179,75329,000275,000414,0000000000000000000
       Accounts payable 
51,567
18,590
26,815
25,683
50,966
45,659
119,609
67,868
44,972
37,518
34,767
62,588
84,849
208,737
112,818
74,436
805,037
921,409
15,887,531
949,429
1,932,901
1,283,568
206,898
206,8981,283,5681,932,901949,42915,887,531921,409805,03774,436112,818208,73784,84962,58834,76737,51844,97267,868119,60945,65950,96625,68326,81518,59051,567
       Other Current Liabilities 
74,937
68,147
46,133
62,094
55,041
58,628
62,142
81,207
38,881
43,968
32,183
19,179
0
0
35,779
30,318
1,232,483
887,983
5,378,046
518,056
593,060
1,108,254
231,461
231,4611,108,254593,060518,0565,378,046887,9831,232,48330,31835,7790019,17932,18343,96838,88181,20762,14258,62855,04162,09446,13368,14774,937
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
93,669,389
103,441,901
125,753,061
162,486,611
196,798,358
213,369,433
229,010,026
229,010,026213,369,433196,798,358162,486,611125,753,061103,441,90193,669,3890000000000000000
       Other Liabilities 
0
0
0
0
0
0
0
0
0
0
11,500
11,500
11,800
15,812
19,353
168,461
93,309,389
103,384,977
125,642,561
162,486,611
193,930,419
207,126,554
0
0207,126,554193,930,419162,486,611125,642,561103,384,97793,309,389168,46119,35315,81211,80011,50011,5000000000000
       Deferred Long Term Liability 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
23,091
25,404
25,155
27,582
31,383
0
031,38327,58225,15525,40423,09100000000000000000
> Total Stockholder Equity
527,736
688,697
693,958
645,852
650,943
658,042
707,038
814,471
1,461,580
1,518,172
1,545,022
1,376,238
1,497,477
1,395,796
1,449,017
1,739,667
13,801,760
19,337,031
18,992,084
21,223,053
21,134,912
22,553,334
21,411,956
21,411,95622,553,33421,134,91221,223,05318,992,08419,337,03113,801,7601,739,6671,449,0171,395,7961,497,4771,376,2381,545,0221,518,1721,461,580814,471707,038658,042650,943645,852693,958688,697527,736
   Common Stock
278,891
517,213
594,795
594,795
594,795
594,795
594,795
594,795
676,795
676,795
1,353,590
1,353,590
1,353,590
1,353,590
1,353,590
1,353,590
4,259,195
4,940,629
4,940,629
4,940,629
4,940,629
4,940,629
0
04,940,6294,940,6294,940,6294,940,6294,940,6294,259,1951,353,5901,353,5901,353,5901,353,5901,353,5901,353,590676,795676,795594,795594,795594,795594,795594,795594,795517,213278,891
   Retained Earnings 
73,400
27,839
6,410
0
0
0
13,123
115,678
96,070
132,621
19,018
0
0
0
46,489
293,756
2,031,867
3,251,552
4,380,447
6,025,913
6,112,142
6,533,450
6,508,547
6,508,5476,533,4506,112,1426,025,9134,380,4473,251,5522,031,867293,75646,48900019,018132,62196,070115,67813,1230006,41027,83973,400
   Capital Surplus 00000000000000000000000
   Treasury Stock00000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
62,379
593,227
73,762
-1,426,936
-838,785
-1,013,165
-15,104
0
0-15,104-1,013,165-838,785-1,426,93673,762593,22762,379000000000000000



Balance Sheet

Currency in CNY. All numbers in thousands.




Cash Flow

Currency in CNY. All numbers in thousands.




Income Statement

Currency in CNY. All numbers in thousands.


Latest Income Statement (annual, 2023-12-31)

Gross Profit (+$)
totalRevenue52,974,104
Cost of Revenue-9,242,984
Gross Profit43,731,12143,731,121
 
Operating Income (+$)
Gross Profit43,731,121
Operating Expense-28,583,289
Operating Income24,390,81615,147,832
 
Operating Expense (+$)
Research Development-
Selling General Administrative554,370
Selling And Marketing Expenses-
Operating Expense28,583,289554,370
 
Net Interest Income (+$)
Interest Income-
Interest Expense--
Other Finance Cost-0
Net Interest Income-
 
Pretax Income (+$)
Operating Income24,390,816
Net Interest Income-
Other Non-Operating Income Expenses-
Income Before Tax (EBT)-890,39524,390,816
EBIT - interestExpense = 0
-176,558
-176,558
Interest Expense-
Earnings Before Interest and Taxes (EBIT)--890,395
Earnings Before Interest and Taxes (EBITDA)-
 
After tax Income (+$)
Income Before Tax-890,395
Tax Provision--540,598
Net Income From Continuing Ops-349,798-349,798
Net Income-176,558
Net Income Applicable To Common Shares-
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-0
 

Technical Analysis of Biocause
The psychology behind the price

Technical indicators reflecting market sentiment and the collective psychology of you and other traders. Your emotions and other traders' emotions, such as fear and greed, play a significant role in driving price movements.

General trend

First of all, I'm going to put something in the back of your mind. One of the most stable factors that gives you more confidence as a trader: the general trend of Biocause. The general trend of Biocause is BEARISH with 100.0% confidence. It is very important for your mental being to use each indicator with this in mind. But beware, also the general trend flips once in a while! You can use moving averages to determine Biocause's overall trend. For convenience I use the most commonly used moving averages: 20, 50, 100 & 200. Of course you can use other moving averages or other indicators to determine the trend.

Indicator phases

Some of the indicators I use have 3 zones: overbought, oversold and neutral. Transitions between these zones (market phases) provide valuable trading signals and insights. Expecially with the general trend mind, I use the highlighted phases:

Indicator zone transitionsBullish trend (-100.0%) Bearish trend (100.0%)
Overbought to neutralBullish pullback=Bearish reversal
Upper to lower neutralBullish correction=Bearish continuation
Nuetral to oversoldOversold=Oversold
Oversold to neutralBullish reversal=Bearish correction
Lower to upper neutralBullish continuation=Bearish pullback
Nuetral to overboughtOverbought=Overbought

1. Price Targets

1.1 Support & Resistance

Support and resistance are levels on a price chart that act as barriers or zones where the price of an asset tends to stop, reverse, or experience a significant amount of buying or selling pressure.

Support is a price level at which demand for an asset is strong enough to prevent the price from falling further.
Resistance is a price level at which selling pressure becomes significant enough to prevent the price of an asset from rising further.


Score

Let's take a look at the Support & Resistance of Hubei Biocause Pharmaceutical.

The long score for the Support & Resistance is 0/1.
The longshort score for the Support & Resistance is 0/(-1 +1).

  • Between support/resistance: The price is trading between support and resistance lines.

The bullish price targets are: 2.41 < 2.55 < 2.59.

The bearish price targets are: 2.11.

Tweet this
Hubei Biocause Pharmaceutical Daily Support & Resistance Chart

2. Trend Indicators

2.1 Moving Averages

Shows the moving average of the selected period.

  • Moving averages are lagging trend indicators.
  • There are many types of moving averages.
  • Moving averages are also used within other indicators.

Score

Let's take a look at the Moving Averages of Hubei Biocause Pharmaceutical. The current mas is .

The long score for the Moving Averages is 0/14.
The longshort score for the Moving Averages is -14/(-14 +14).

  • MA 20 trending down: The MA 20 is trending down. -1
  • Close < MA 20: The price is below the MA 20. -1
  • MA 20 < MA 50: The MA 20 is lower than the MA 50. -1
  • MA 20 < MA 100: The MA 20 is lower than the MA 100. -1
  • MA 20 < MA 200: The MA 20 is lower than the MA 200. -1
  • MA 50 trending down: The MA 50 is trending down. -1
  • Close < MA 50: The price is below the MA 50. -1
  • MA 50 < MA 100: The MA 50 is lower than the MA 100. -1
  • MA 50 < MA 200: The MA 50 is lower than the MA 200. -1
  • MA 100 trending down: The MA 100 is trending down. -1
  • Close < MA 100: The price is below the MA 100. -1
  • MA 100 < MA 200: The MA 100 is lower than the MA 200. -1
  • MA 200 trending down: The MA 200 is trending down. -1
  • Close < MA 200: The price is below the MA 200. -1

Directionalities and relatives.

Moving AverageAmount of candlesTrendPrice +/-vs. MA 50vs. MA 100vs. MA 200
MA 2020
MA 5050-
MA 100100--
MA 200200---

Explanation: https://www.youtube.com/watch?v=xwW8h0lrQ-I

Hubei Biocause Pharmaceutical Daily Moving Averages Chart
2.2 Moving Average Convergence/Divergence (MACD)

Shows the momentum of the selected period based on two moving averages.

  • MACD is a lagging momentum indicator.
  • Uses two moving averages.
  • Can show buy or sell signals based on momentum.
  • Can show overbought. and oversold. levels.

Score

Let's take a look at the Moving Average Convergence/Divergence (MACD) of Hubei Biocause Pharmaceutical. The current macd is -0.07726416.

The long score for the Moving Average Convergence/Divergence (MACD) is 1/4.
The longshort score for the Moving Average Convergence/Divergence (MACD) is -2/(-4 +4).

  • MACD line < signal line: The MACD line is below the signal line, which indicates a bearish signal in the market. This means that the negative momentum is currently stronger than the average momentum, suggesting that sellers are more active than buyers, and there's a higher probability of the Biocause price going down in the near term. -2
  • MACD < 0: The MACD is below the zero line (centerline), it indicates a bearish signal for Biocause. This means that the short-term moving average is lower than the long-term moving average, signaling negative momentum and suggesting a higher likelihood of the Biocause price continuing to fall in the near future. It indicates that sellers are gaining control, and there is negativism in the market, leading to potential price decreases. -1
  • Trending up: The MACD line is trending up. This indicates that the short-term moving average is rising faster than the long-term moving average, suggesting positive momentum in the market. This signals that buyers are becoming more active and confident, leading to potential price increases as traders anticipate further gains and are willing to buy at higher prices. +1
Hubei Biocause Pharmaceutical Daily Moving Average Convergence/Divergence (MACD) ChartHubei Biocause Pharmaceutical Daily Moving Average Convergence/Divergence (MACD) Chart
2.3 Directional Movement Index (DMI)

The DMI is a collection of 3 indicators: +DI (Plus Direction Indicator), -DI (Minus Direction Indicator) and ADX (Average Directional Index). The ADX helps you determine the strength of a trend.


Score

Let's take a look at the Directional Movement Index (DMI) of Hubei Biocause Pharmaceutical. The current adx is 20.47.

The long score for the Directional Movement Index (DMI) is 0/7.
The longshort score for the Directional Movement Index (DMI) is -2/(-7 +7).

  • PLUS_ID < MINUS_DI: The +DI line is below the -DI line. This indicates a bearish signal in the market, as the negative directional movement is currently stronger than the positive directional movement, showing that sellers have the upper hand. Market psychology suggests that traders are pessimistic, expecting further price decreases, and are more willing to sell Biocause shares, leading to potential downward momentum in its price. -1
  • PLUS_ID < MINUS_DI && ADX < 25 && ADX trending up: The ADX is below 25 and indicates a weak or no trend. However, the ADX is rising and a new bearish trend could be forming. -1
Hubei Biocause Pharmaceutical Daily Directional Movement Index (DMI) Chart
2.4 Parabolic SAR

Shows the current trend and potential entry and exit signals.

  • Parabolic SAR (stop and reverse) is a lagging trend indicator.
  • Shows the current trend.
  • Shows potential entry signals.
  • Shows  potential exit signals.
  • Can be used to place trailing stoplosses..

Score

Let's take a look at the Parabolic SAR of Hubei Biocause Pharmaceutical. The current sar is 2.4214251.

The long score for the Parabolic SAR is 0/1.
The longshort score for the Parabolic SAR is -1/(-1 +1).

  • Close < SAR: The price is below the SAR. It's generally considered a bearish signal. -1
Hubei Biocause Pharmaceutical Daily Parabolic SAR Chart

3. Momentum Indicators

3.1 Relative Strength Index (RSI)

Measures the speed and change of price movements.

  • Leading momentum indicator, meaning the signals are instant.
  • Ranges between 0 and 100.
  • Above 70 is considered overbought.
  • Below 30 is considered oversold.
  • Above or below 50 can also be used to determine price trend or support and resistance.
  • RSI divergence looks at a deviation between RSI and price movement. Penketrading automatically calculates RSI divergences.
  • Can be used in many different ways

Score

Let's take a look at the Relative Strength Index (RSI) of Hubei Biocause Pharmaceutical. The current rsi is 39.58. The current phase is Continuation in bear market.

The long score for the Relative Strength Index (RSI) is 1/13.
The longshort score for the Relative Strength Index (RSI) is -2/(-13 +13).

  • Continuation in bear market: Downtrend continues after a consolidation or pullback. Hold or add to short positions.
  • Trending up: The RSI is trending up. +1
Hubei Biocause Pharmaceutical Daily Relative Strength Index (RSI) ChartHubei Biocause Pharmaceutical Daily Relative Strength Index (RSI) Chart
3.2 Stochastic Oscillator

Compares a certain price to multiple prices ranging over time.

  • Leading momentum indicator, meaning the signals are instant.
  • Used to determine overbought and oversold areas much like the RSI.
  • Ranges between 0 and 100.
  • Above 80 is considered overbought.
  • Below 20 is considered oversold.
  • Consists of two lines named K and D.
  • K compares the highest high and lowest low on the selected price range.
  • The D line is a moving average of the K line.
  • Can be used to spot divergences

Score

Let's take a look at the Stochastic Oscillator of Hubei Biocause Pharmaceutical. The current phase is Continuation in bear market.

The long score for the Stochastic Oscillator is 3/6.
The longshort score for the Stochastic Oscillator is 2/(-6 +6).

  • STOCH < 50: The STOCH %K is below 50. There are more sellers than buyers. -1
  • STOCH %K line > STOCH %D line: The STOCH %K line is above the STOCH %D line, which indicates a bullish signal in the market. This means that the positive momentum is currently stronger than the average momentum, suggesting that buyers are more active than sellers, and there's a higher probability of the Biocause price going up in the near term. +2
  • Trending up: The STOCH %K is trending up. +1
Hubei Biocause Pharmaceutical Daily Stochastic Oscillator ChartHubei Biocause Pharmaceutical Daily Stochastic Oscillator Chart
3.3 Commodity Channel Index (CCI)

Measures the difference between the current price and the historical average price.

  • Lagging or leading Momentum indicator
  • When the CCI is above zero, the price is above the historical average
  • When the CCI is below zero, the price is below the historical average
  • Used for spotting trends
    • If the CCI moves from negative or near zero to positive 100 that might indicate an uptrend
    • If the CCI moves from positive or near zero to negative -100 that might indicate a downtrend

Score

Let's take a look at the Commodity Channel Index (CCI) of Hubei Biocause Pharmaceutical. The current cci is -114.08876697.

The long score for the Commodity Channel Index (CCI) is 0/1.
The longshort score for the Commodity Channel Index (CCI) is -1/(-1 +1).

  • CCI < -100: The CCI is below -100, it indicates that the price is significantly below its average, suggesting a potential oversold condition. -1
Hubei Biocause Pharmaceutical Daily Commodity Channel Index (CCI) ChartHubei Biocause Pharmaceutical Daily Commodity Channel Index (CCI) Chart
3.4 Chande Momentum Oscillator (CMO)

Measures the difference between the sum of recent gains and the sum of recent losses. Then divides the result by the sum of all price movements in that period.

  • Lagging momentum indicator
  • Ranges between +100 and -100
  • Considered overbought above +50
  • Considered oversold below -50
  • It's possible to add a moving average that acts as a signal line

Score

Let's take a look at the Chande Momentum Oscillator (CMO) of Hubei Biocause Pharmaceutical. The current cmo is -20.65143709.

The long score for the Chande Momentum Oscillator (CMO) is 0/1.
The longshort score for the Chande Momentum Oscillator (CMO) is -1/(-1 +1).

  • CMO < 0: The CMO is below 0, the momentum of the price is negative, indicating a potential downtrend in the price. -1
Hubei Biocause Pharmaceutical Daily Chande Momentum Oscillator (CMO) ChartHubei Biocause Pharmaceutical Daily Chande Momentum Oscillator (CMO) Chart
3.5 Williams %R

 Shows the current price relative to the highest high over the last 14 days.
 

  • Lagging momentum indicator
  • Ranging between 0 and -100
  • Above -20 is considered overbought
  • Below -80 is considered oversold
  • Is prone to give false signals

Score

Let's take a look at the Williams %R of Hubei Biocause Pharmaceutical. The current willr is -70.27027027.

The long score for the Williams %R is 0/1.
The longshort score for the Williams %R is 0/(-1 +1).

  • WILLR between -80 and -20: The Williams %R is between -80 and -20. This indicates that Biocause is trading in a neutral price range, neither oversold nor overbought, suggesting a balanced market condition without any extreme price signals.
Hubei Biocause Pharmaceutical Daily Williams %R ChartHubei Biocause Pharmaceutical Daily Williams %R Chart

4. Volatility Indicators

4.1 Bollinger Bands

Shows if the price is to high or to low relative to an average.

  • Lagging volatility indicator
  • Uses 3 bands: one upper, one lower and one in the middle
  • Works best when the middle band reflects an intermediate trend (MA20).
  • When the price is moving closer to the upper band, the market might be overbought
  • When the price is moving closer to the lower band, the market might be oversold 

Score

Let's take a look at the Bollinger Bands of Hubei Biocause Pharmaceutical.

Hubei Biocause Pharmaceutical Daily Bollinger Bands Chart
4.2 Average True Range (ATR)
Measures market volatility
  • Leading volatility indicator
  • Can be used to determine stop-loss positions
  • Calculated by:
    • Current high minus the current low
    • Current high minus the previous close
    • Current low minus the previous close
  • The larger the range of the candles, the greater the ATR value

Score

Let's take a look at the Average True Range (ATR) of Hubei Biocause Pharmaceutical. The current atr is 0.08519967.

Hubei Biocause Pharmaceutical Daily Average True Range (ATR) ChartHubei Biocause Pharmaceutical Daily Average True Range (ATR) Chart

5. Volume Indicators

5.1 On-Balance Volume (OBV)

 Measures market volatility

  • Leading momentum indicator
  • Calculation:
    • If the closing price is above the previous closing price: OBV = previous OBV + current volume
    • If the closing price is below the previous closing price: OBV = previous OBV - current volume
    • If the closing price is the same as the previous closing price than the OBV is the same.
  • Can be used to confirm price trends
  • Can be used with divergences

Score

Let's take a look at the On-Balance Volume (OBV) of Hubei Biocause Pharmaceutical. The current obv is -662,354,565.

Hubei Biocause Pharmaceutical Daily On-Balance Volume (OBV) ChartHubei Biocause Pharmaceutical Daily On-Balance Volume (OBV) Chart
5.2 Money Flow Index (MFI)

Measures the flow of money in and out of a security

  • Lagging momentum indicator
  • Looks like RSI but uses volume as an extra metric (RSI only considers price)
  • Above 80 is considered overbought
  • Below 20 is considered oversold
  • Can be used with divergences

Score

Let's take a look at the Money Flow Index (MFI) of Hubei Biocause Pharmaceutical. The current mfi is 38.94.

The long score for the Money Flow Index (MFI) is 0/2.
The longshort score for the Money Flow Index (MFI) is -1/(-2 +2).

  • MFI < 50: -1
Hubei Biocause Pharmaceutical Daily Money Flow Index (MFI) ChartHubei Biocause Pharmaceutical Daily Money Flow Index (MFI) Chart

6. Summary

6.1. Notifications

TypeNotificationDate
PenkeCurrently no notifications for Hubei Biocause Pharmaceutical.

6.2. Trading Signals

Below you will find trading signals as the indicator is commonly used. This doesn't mean you should use it that way. Learn from these, but don't use them blindly. I recommend using at least 4 indicators, 1 from each category: trend, momentum, volatility and volume.

DateIndicatorSignal
2023-11-21CCI LONG ENTRY SHORT CLOSE100 crossover to upside
2023-11-22STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-23STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2023-11-24STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2023-11-27DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2023-11-28MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-11-30BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-01STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-04STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-05BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-06STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-08STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2023-12-11STOCH SHORT EXITThe %K line crosses above the %D line.
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-12MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-13STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
MFI SHORT ENTRY LONG CLOSE20 crossover to downside
2023-12-15STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-18STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2023-12-20BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2023-12-21STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-25STOCH LONG EXITThe %K line crosses below the %D line.
2023-12-27STOCH SHORT EXITThe %K line crosses above the %D line.
2023-12-28SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
RSI LONG ENTRY SHORT CLOSE30 crossover to upside
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
MFI LONG ENTRY SHORT CLOSE20 crossover to upside
2023-12-29MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-02STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-03STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-08STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-10SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
2024-01-11STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-12STOCH LONG EXITThe %K line crosses below the %D line.
2024-01-16STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-17STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-18MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-22STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-23STOCH SHORT EXITThe %K line crosses above the %D line.
2024-01-24RSI LONG ENTRY SHORT CLOSE30 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-25MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-01-26DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI LONG ENTRY SHORT CLOSE100 crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-01-29ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-01-30CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-01-31DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-02-01MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-02-02BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-02-05ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-02-06RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-02-08CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-19CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-02-20MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-21DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
SAR LONG ENTRY SHORT CLOSEThe price broke the SAR to the upside.
STOCH SHORT EXITThe %K line crosses above the %D line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-02-27WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-02-28STOCH LONG EXITThe %K line crosses below the %D line.
2024-02-29STOCH SHORT EXITThe %K line crosses above the %D line.
WILLR LONG ENTRY SHORT CLOSE-20 crossover to upside
2024-03-04STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-05CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-07WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-08MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
2024-03-11DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-12MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-13STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-14MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
2024-03-15DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-18MACD LONG ENTRY SHORT CLOSEThe MACD line crosses above the signal line.
DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
2024-03-19STOCH LONG EXITThe %K line crosses below the %D line.
CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-03-21STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-22MACD SHORT ENTRY LONG CLOSEThe MACD line crosses below the signal line.
DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-03-25SAR SHORT ENTRY LONG CLOSEThe price broke the SAR to the downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-03-26STOCH SHORT EXITThe %K line crosses above the %D line.
2024-03-27STOCH LONG EXITThe %K line crosses below the %D line.
2024-03-28STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-01DMI LONG ENTRY SHORT CLOSEThe +DI crossed the -DI to the upside. The trend is reversing to an up trend.
CMO LONG ENTRY SHORT CLOSEZero line crossover to upside
ATR LONG ENTRY SHORT CLOSEPrice closed above (close + ATR).
2024-04-02CMO SHORT ENTRY LONG CLOSEZero line crossover to downside
2024-04-03DMI SHORT ENTRY LONG CLOSEThe +DI crossed the -DI to the downside. The trend is reversing to a down trend.
STOCH LONG EXITThe %K line crosses below the %D line.
2024-04-10CCI SHORT ENTRY LONG CLOSE-100 crossover to downside
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
2024-04-12BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
2024-04-15STOCH SHORT EXITThe %K line crosses above the %D line.
2024-04-16STOCH LONG EXITThe %K line crosses below the %D line.
WILLR SHORT ENTRY LONG CLOSE-80 crossover to downside
BB LONG ENTRY SHORT CLOSEPrice closed below the lower band.
ATR SHORT ENTRY LONG CLOSEPrice closed below (close - ATR).
2024-04-17RSI LONG ENTRY SHORT CLOSE30 crossover to upside
STOCH SHORT EXITThe %K line crosses above the %D line.

6.3. Candlestick Patterns

Hubei Biocause Pharmaceutical Daily Candlestick Chart
DateCandlestick Pattern

6.4. Technical Score

Let's check the technical score of Hubei Biocause Pharmaceutical based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5039.582
Ma 20Greater thanMa 502.450
Ma 50Greater thanMa 1002.546
Ma 100Greater thanMa 2002.704
OpenGreater thanClose2.270
Total0/5 (0.0%)
Penke

Good job! You gained 25 XP and 0   0   10 . What's next:

  • Share my analysis of Biocause with someone you think should read this too:
  • Are you bullish or bearish on Biocause? Let me know what you think in the comments.
  • Do you want an email if I find something interesting about Biocause? Add an email alert using the form below.
  • Join the community if you want to keep your earnings and track your progress: Join the community
  • Is this analysis useful to you? Support me via But Me a Coffee. I'll analyze the stock market faster for you!

Get notifications about Hubei Biocause Pharmaceutical

I send you an email if I find something interesting about Hubei Biocause Pharmaceutical.


Comments

How you think about this?

Leave a comment

Stay informed about Hubei Biocause Pharmaceutical.

Receive notifications about Hubei Biocause Pharmaceutical in your mailbox!